Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session
$ALB
$AMAM
$AMCX
$APGN
Major Chemicals
Industrials
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Gainers
- Ibio Inc (NYSE:IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program.
- Universal Security Instruments, Inc. (NYSE:UUU) rose 40.6% to $3.09 after the company reported a year-over-year increase in Q3 EPS and revenues.
- SciSparc Ltd. (NASDAQ:SPRC) gained 25.4% to $1.1410 after the company announced its MitoCareX Bio joint venture achieved achieved its first milestone pursuant to the March 10, 2022 Founders and Investment Agreement.
- Cyclo Therapeutics, Inc. (NASDAQ:CYTH) surged 22.4% to $1.3952.
- AMC Networks Inc. (NASDAQ:AMCX) shares jumped 20.9% to $24.60 after reporting better-than-expected Q4 results.
- EBET, Inc. (NASDAQ:EBET) gained 18.4% to $0.6321 following strong Q4 results and guidance from DraftKings.
- Apexigen, Inc. (NASDAQ:APGN) jumped 15.8% to $1.10.
- Telephone and Data Systems, Inc. (NYSE:TDS) rose 15% to $12.80 after the company posted Q4 results and increased its common share dividend from $0.18 to $0.185.
- Celyad Oncology SA (NASDAQ:CYAD) jumped 14.9% to $1.31.
- IVERIC bio, Inc. (NASDAQ:ISEE) surged 14.9% to $22.98 after the FDA accepted the company's New Drug Application for avacincaptad pegol.
- Lanvin Group Holdings Limited (NYSE:LANV) gained 14.7% to $8.20.
- DraftKings Inc. (NASDAQ:DKNG) shares climbed 14.6% to $20.41 after the company reported better-than-expected Q4 results and raised FY23 guidance. The company reported a 31% year-over-year increase in Monthly Unique Payers.
- United States Cellular Corporation (NYSE:USM) gained 14.5% to $24.04 following Q4 results.
- Kinsale Capital Group, Inc. (NASDAQ:KNSL) jumped 13.7% to $332.00 following upbeat Q4 results.
- Nogin Inc (NASDAQ:NOGN) rose 13.6% to $0.7260 after the company and Seychelles Imports LLC announced an agreement under which Sychelles will utilize Nogin's Customer Data Platform and Marketing Automation and Marketplace Dropship.
- HubSpot, Inc. (NYSE:HUBS) gained 12.6% to $407.65 after the company reported better-than-expected Q4 results and issued strong guidance for Q1 and FY23.
- Pediatrix Medical Group, Inc. (NYSE:MD) jumped 11.8% to $16.85 following strong quarterly sales.
- Inozyme Pharma, Inc.. (NASDAQ:INZY) gained 11.3% to $3.0050. Inozyme Pharma, on Thursday, announced topline pharmacokinetic (PK), pharmacodynamic (PD), and safety data from the ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE).
- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) gained 9.3% to $1.07.
- SharpLink Gaming Ltd. (NASDAQ:SBET) rose 7.8% to $0.56.
Losers
- Arqit Quantum Inc. (NASDAQ:ARQQ) shares dipped 39.7% to $1.5250 after the company announced a $20 million registered direct offering.
- Universal Electronics Inc. (NASDAQ:UEIC) dropped 29.9% to $17.15 after reporting downbeat Q4 results.
- Intuitive Machines, Inc. (NASDAQ:LUNR) fell 24% to $33.77.
- Verde Clean Fuels, Inc. (NASDAQ:VGAS) declined 22.2% to $8.25. Verde recently announced a joint venture with Diamondback Energy.
- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) dropped 20.4% to $0.7601.
- DZS Inc. (NASDAQ:DZSI) fell 20.2% to $9.62 after the company reported worse-than-expected Q4 results.
- XP Inc. (NASDAQ:XP) fell 17.6% to $13.09 after the company reported Q4 financial results.
- AXT, Inc. (NASDAQ:AXTI) fell 16.3% to $4.94 after the company reported worse-than-expected Q4 revenue.
- RE/MAX Holdings, Inc. (NYSE:RMAX) dropped 16.2% to $19.13 following downbeat quarterly results.
- Cerberus Cyber Sentinel Corporation (NASDAQ:CISO) fell 16.2% to $0.8211. Cerberus Cyber Sentinel terminated its secondary share sale previously announced on February 13.
- Stem Inc (NYSE:STEM) fell 15.8% to $8.20 after the company reported worse-than-expected Q4 results.
- Cognex Corporation (NASDAQ:CGNX) shares fell 15.2% to $46.83 after the company reported worse-than-expected Q4 results.
- Axcella Health Inc (NASDAQ:AXLA) fell 13.8% to $0.62. Axcella shares climbed over 19% on Thursday after the company announced FDA clearance of its IND application to initiate a phase 2b/3 trial in the U.S. for AXA1125.
- Cooper-Standard Holdings Inc. (NYSE:CPS) dropped 12.3% to $15.50 following weak quarterly results.
- VolitionRX Ltd (NASDAQ:VNRX) shares fell 12.3% to $1.79 after the company reported pricing of $7.525 million underwritten public offering of common stock.
- Natural Health Trends Corp. (NASDAQ:NHTC) dropped 12% to $5.89.
- Boxed Inc (NYSE:BOXD) fell 11.8% to $0.6307 after jumping 63% on Thursday.
- Applied Therapeutics Inc (NASDAQ:APLT) shares fell 11.3% to $1.0384 after gaining 17% on Thursday. Applied Therapeutics announced sorbitol reduction data from the ongoing global Phase 3 INSPIRE trial of oral AT-007 in approximately 50 patients with SORD Deficiency in the U.S. and Europe.
- VolitionRx Limited (NASDAQ:VNRX) fell 10.7% to $1.82 after the company announced pricing of a $4.3 million share common stock offering at $1.75 per share.
- American Axle & Manufacturing Holdings, Inc. (NYSE:AXL) dropped 9.8% to $9.06 following downbeat quarterly earnings.
- Albemarle Corporation (NYSE:ALB) fell 9.3% to $258.86. Albemarle recently reported better-than-expected Q4 adjusted EPS results.
- Pop Culture Group Co Ltd (NASDAQ:CPOP) fell 8.7% to $0.9133.
- Piedmont Lithium Inc. (NASDAQ:PLL) dropped 8.7% to $67.06. Piedmont Lithium and LG Chem signed equity investment and binding offtake agreements.
- Dropbox, Inc. (NASDAQ:DBX) dropped 8.1% to $22.02 following Q4 results.
- Ambrx Biopharma Inc - ADR (NYSE:AMAM) fell 7.8% to $2.5630. Ambrx Biopharma shares jumped 56% on Thursday after the company announced initial data from its ongoing Phase 1 APEX-01 trial of ARX517, Ambrx's proprietary anti-PSMA ADC, in prostate cancer patients.
- Natwest Group PLC - ADR (NYSE:NWG) fell 6.6% to $6.95 after the company reported Q4 financial results.
- Moderna Inc (NASDAQ:MRNA) shares dropped 6.1% to $161.83 after the company released interim Phase 3 safety and immunogenicity results for its mRNA-1010 influenza candidate, which did not achieve non-inferiority for the Influenza B strains.
Now Read This: Top 5 Tech And Telecom Stocks That Are Set To Fly This Month